http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2153833-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f81c6fa05269fed8e8665a8e72778ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 |
| filingDate | 2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2153833-A1 |
| titleOfInvention | ADP-receptor antagonist for treatment of inflammatory disease |
| abstract | A method of treating cardiovascular complications of inflammatory disease in an individual with an established inflammatory disease and having symptoms of active inflammation comprises a step of treating the individual with a suitable amount of an ADP-receptor antagonist. The inflammatory disease includes a disease selected from the group consisting of rheumatoid arthritis and psoriatic arthritis. The ADP-receptor antagonist may be clopridogel (PLAVIX). The method of the invention has the effect of reducing the risk of a patient with active inflammation having an atherothrombotic event as a side-effect of inflammatory disease. The patients are treated with from 5 to 900mg of an ADP-antagonist daily, with an optional loading dose of an ADP-receptor antagonist of between 300 and 900mg. |
| priorityDate | 2008-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 141.